Heron Therapeutics, Inc. — Q1 2019 Form 10-Q Summary
Business context and reporting period
Heron Therapeutics is a commercial-stage biotechnology company developing and commercializing treatments for chemotherapy-induced nausea and vomiting and postoperative pain. The filing covers the three months ended March 31, 2019, with comparative results for the three months ended March 31, 2018.
- Commercial products: SUSTOL and CINVANTI.
- Pipeline: HTX-011 for postoperative pain and next-generation candidate HTX-034.
- CINVANTI received FDA approval for a 2-minute intravenous injection in February 2019, expanding beyond its prior 30-minute infusion administration.
Financial performance and key metrics
| Metric | Q1 2019 | Q1 2018 | Change |
|---|---|---|---|
| Net product sales | $31.6 million | $11.6 million | Up $20.0 million |
| Cost of product sales | $15.0 million | $3.1 million | Up $11.8 million |
| Gross profit | $16.6 million | $8.4 million | Up $8.2 million |
| Approximate gross margin | 52.7% | 72.9% | Down 20.2 percentage points |
| Research and development | $43.0 million | $39.6 million | Up $3.4 million |
| General and administrative | $9.6 million | $7.0 million | Up $2.6 million |
| Sales and marketing | $28.7 million | $13.8 million | Up $14.9 million |
| Operating loss | $64.7 million | $52.0 million | Loss increased $12.7 million |
| Net loss | $63.0 million | $52.3 million | Loss increased $10.7 million |
| Net loss per share | $0.80 | $0.81 | Improved by $0.01 |
| Cash used in operating activities | $49.0 million | $61.7 million | Use decreased $12.7 million |
CINVANTI net sales were $28.0 million, compared with $5.2 million in the prior-year quarter. SUSTOL net sales declined to $3.6 million from $6.4 million.
Cash, cash equivalents and short-term investments totaled $289.2 million at March 31, 2019, compared with $332.4 million at December 31, 2018. Cash and cash equivalents alone were $23.5 million. Net cash provided by investing activities was $34.1 million, primarily from maturities and sales of short-term investments, while financing activities provided $6.5 million from stock option exercises.
Total assets were $435.8 million and total stockholders’ equity was $331.8 million at March 31, 2019. The company reported an accumulated deficit of $1.024 billion.
Debt, liquidity and material balance-sheet changes
- Convertible notes to related parties had a carrying value of $4.8 million, representing $6.9 million of principal less a $2.1 million debt discount. The notes bear interest at 6%, mature in May 2021, are secured by substantially all company assets and are convertible into approximately 8.6 million shares.
- The company repaid the remaining $25.0 million principal and $0.2 million accrued interest on its subordinated secured promissory note in August 2018; no balance remained at March 31, 2019.
- Adoption of the lease accounting standard on January 1, 2019 added $13.1 million of right-of-use lease assets and $13.8 million of lease liabilities at March 31, 2019, without a material impact on earnings or liquidity.
- Management stated that available cash, cash equivalents and short-term investments were sufficient to fund operations for at least one year from the filing date.
Material changes versus the prior comparable period
- Revenue growth was driven by the continued commercial ramp of CINVANTI, while SUSTOL sales declined amid increased competition, including generic palonosetron entry.
- Cost of product sales increased disproportionately to revenue, partly because of a $1.6 million write-off of short-dated SUSTOL inventory.
- Sales and marketing expense more than doubled, reflecting preparation for a potential HTX-011 launch and $6.0 million of stock-based compensation related to the retirement of the company’s President.
- Research and development expense increased primarily because of higher personnel, other operating and stock-based compensation costs, partially offset by lower HTX-011 and SUSTOL-related costs.
- Stock-based compensation increased to $17.9 million from $7.7 million.
Outlook, commentary, risks and unusual items
Management expects continued substantial operating losses and negative operating cash flow while it funds product development, regulatory activities and commercialization. No quantitative revenue or earnings guidance was provided.
- After the quarter ended, on April 30, 2019, the FDA issued a Complete Response Letter for HTX-011. The FDA requested additional chemistry, manufacturing and controls and non-clinical information. The filing states that the FDA identified no clinical safety or efficacy issues and did not require additional clinical studies or data analyses.
- In April 2019, the EMA validated the HTX-011 Marketing Authorisation Application. A CHMP opinion was anticipated in the first half of 2020.
- HTX-011 launch timing and investment plans are subject to regulatory approval, manufacturing readiness and additional information requirements.
- Revenue is highly concentrated: three customers represented 97.7% of Q1 2019 net product sales and 99.0% of accounts receivable at March 31, 2019.
- Key risks include dependence on SUSTOL and CINVANTI, reimbursement and pricing pressure, generic and branded competition, manufacturing and supply concentration, regulatory delays, product liability, intellectual-property challenges and the need for future capital.
- The company had no legal proceedings reported as material and no off-balance-sheet arrangements.
Most important facts for investors to verify
- Whether CINVANTI’s growth can offset declining SUSTOL sales and support improving gross margins.
- The required CMC and non-clinical submissions and expected timing for resolving the HTX-011 FDA Complete Response Letter.
- Quarterly operating cash burn relative to the $289.2 million liquidity balance and management’s funding horizon.
- The sustainability of customer concentration and the collectability of the $74.0 million accounts receivable balance.
- The magnitude and recurring nature of stock-based compensation, launch-preparation costs and potential inventory write-downs.
- Potential dilution from approximately 8.6 million shares issuable under the convertible notes, in addition to outstanding options and warrants.